Emergent Biosolutions Expands Presence In Germany
Acquires Vivacs GmbH Along with Rights to Modified Vaccinia Virus Ankara (MVA) Strain and Monoclonal Vector Technology Platform (MVAtorTM)
GAITHERSBURG, MD., August 03, 2006—Emergent BioSolutions Inc., a privately held biopharmaceutical company, today announced it has completed the acquisition of Vivacs GmbH, a privately held biotechnology company based in Munich, Germany. Financial details of the transaction were [...]
In: Emergent BioSolutions, Fuad El-Hibri, Vivacs GmbH · Tagged with: Biotechnology and Pharmaceuticals, Business, Chief executive officer, Emergent BioSolutions, Germany, Infectious disease, Maryland, Munich
Emergent Biosolutions And Hpa Announce Botulinum Vaccine Collaboration
Image via Wikipedia
Botulism Ranks In Cdc’S Category “A” Threat List For Bioweapons
Gaithersburg, MD and London, England—Emergent BioSolutions and the Britishbased Health Protection Agency (HPA) today announced a two-year collaboration for the development of vaccines to prevent botulism.
These two leaders in biodefense vaccines have long-established capabilities in the prevention of botulism dating to the 1950s. In [...]
In: Botulinum Vaccine, Emergent BioSolutions, Fuad El-Hibri · Tagged with: CDC, Centers for Disease Control and Prevention, Emergent BioSolutions, Gulf War, Health, Health Protection Agency, Infectious disease, US